Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @krebs_matt
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @krebs_matt
-
matt krebs proslijedio/la je Tweet
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: https://www.biocentury.com/article/304364 . Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. https://www.biocentury.com/article/304364 All BioCentury coverage of the outbreak is in front of the paywall at https://www.biocentury.com/coronavirus .pic.twitter.com/MR9Bhpq0Pn
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
matt krebs proslijedio/la je Tweet
Folks -
@BioCentury is continuing to cover the#Coronavirus outbreak, which is outside the paywall. This contains the therapeutic & preventive developments, policy actions, and biopharma response.https://www.biocentury.com/coronavirusHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
GSK to provide adjuvant to boost effectiveness, stretch supplies of 2019-nCoV vaccines Details in
@BioCentury from@steveusdin1 here: https://www.biocentury.com/article/304359/gsk-to-provide-adjuvant-to-boost-effectiveness-stretch-supplies-of-2019-ncov-vaccines …#biotech#coronavirusHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
matt krebs proslijedio/la je Tweet
Approval of
@aimmune#peanutallergy therapy huge step in right direction for food allergy patients, families, lends important validation to long-held theory that desensitization is effective to treat food allergies, writes@BioCentury's@Laurenmmartz https://www.biocentury.com/article/304347$AIMTHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
matt krebs proslijedio/la je Tweet
W/ $45M series B led by Decheng,
@mammothbiosci looks to capitalize on IP position around alternative#CRISPR enzyme, expand gene editing capabilities beyond Dx to therapeutic applications.@biocentury's@Laurenmmartz talks w/ CEO Trevor Martin:https://www.biocentury.com/bc-extra/preclinical-news/2020-01-30/crispr-company-mammoth-looks-beyond-diagnostics-decheng- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Arch backs Vizgen’s RNA imaging platform with $14M series A Vizgen is developing technology that will overcome capacity limitations of current single-cell RNA imaging technology? Details and analysis from
@BioCentury s@LaboratoryLiz here:https://www.biocentury.com/biocentury/finance/2020-01-30/arch-thinks-vizgen%E2%80%99s-technology-could-improve-transcriptome-imaging- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Very cool
#biotech newco backed by Flagship Pioneering. Details, analysis and insights in@BioCentury’s Emerging Company Profiles here (subscription/ trial access required):https://www.biocentury.com/biocentury/emerging-company-profile/2020-01-27/ohana-applying-single-cell-sequencing-unexplored- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A+ for the
#biotech Industry today! Biopharma leaders applaud CVS zero co-pay diabetes drug access Details@BioCentury here:https://www.biocentury.com/bc-extra/politics-policy/2020-01-29/industry-leaders-applaud-cvs-zero-co-pay-diabetes-drug-access …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
matt krebs proslijedio/la je Tweet
Seeded by
@atlasventure & Arix,@QuenchBio debuts w/$50M series A to develop gasdermin D inhibitors for inflammatory diseases.@biocentury's@LaboratoryLiz speaks with CEO@SamTruexhttps://www.biocentury.com/bc-extra/company-news/2020-01-27/50m-round-quench-developing-first-class-gasdermin-d-inhibitors- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
matt krebs proslijedio/la je Tweet
Had the pleasure of doing a Fireside Chat with
@snbhatia at#JPM2020, and she is certainly moving the needle on this issue. Having a successful academic entrepreneur speak out is huge. A name to watch in all events.https://www.washingtonpost.com/science/2020/01/29/bias-biotech-funding-has-blocked-women-led-companies/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
HepaRegeniX aims to bring (first-in-class) liver program into clinic with €11M insider round Insights and analysis from
@BioCentury's@BioBonanos here (subscription/trial access required):https://www.biocentury.com/biocentury/finance/2020-01-22/existing-investors-back-german-academic-spinout-its-first-class- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
MONEY RAISED IN 2020 Last week, the
#biotech industry raised $2B. This brings YTD total to $5B. (Totals include overallotments and warrants, and are rounded to the nearest millions.) Wanna run your own analysis? Chk out@BioCentury http://BCIQ.biocentury.com/marketing pic.twitter.com/OMwpcq5EsQ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
J&J developing
#coronavirus#vaccine, at least 9 other vaccines under development. Details@BioCentury here:https://www.biocentury.com/bc-extra/company-news/2020-01-27/jj-developing-coronavirus-vaccine-least-nine-other-vaccines-under- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
matt krebs proslijedio/la je Tweet
At least 8 #2019-nCoV vaccines under development using a variety of technologies. List below. In addition at least three groups are working on mAbs: Regeneron, Vir, and NIH’s NIAID. mAbs might be ready faster and provide both prophylaxis and treatment. https://www.biocentury.com/biocentury/product-development/2020-01-24/coronavirus-outbreak-creating-testbed-new-vaccine-and- …pic.twitter.com/ZZn4WIdRvQ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Was recently asked to look at at the innovative
#biotech cos over past 5 year and their fund raising in Asia. Pulled up these charts so far. The data-set is limited to novel therapeutic cos. Want to do your own analysis? Details: http://bciq.biocentury.com/marketing pic.twitter.com/IjF1qdaIcn
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
matt krebs proslijedio/la je Tweet
Want to know who’s doing what to get CAR Ts to solid tumors? Winnie Pong has sliced and diced the data in
@BioCentury. Take-home message: the majority are going after non-validated targets. Less of the lemming factor than in other areas of IO.https://www.biocentury.com/biocentury/targets-mechanisms/2020-01-24/targets-and-indications-car-t-developers-are-exploring--0 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The race is on to develop therapies and vaccines for the
#coronoavirus outbreak Details@BioCentury here:https://www.biocentury.com/biocentury/product-development/2020-01-24/coronavirus-outbreak-creating-testbed-new-vaccine-and- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This is from Dec, so not sure how I missed it. GREAT analysis from
@BioCentury ‘s@StephenPHansen: A snapshot of where and how pharmas spin out their assets: (subscription/trial access required): https://www.biocentury.com/bc-innovations/product-development/2019-12-19/pharma-spinouts-account-small-percentage-total-newcos- …pic.twitter.com/RbBu5KyXB3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
matt krebs proslijedio/la je Tweet
Good story in
@biocentury last night on who's working on vaccines, diagnostics, & therapeutics for the coronavirus in the headlines incl: Moderna w/NIH, Novavax, US govt's VC firm In-Q-Tel, NY Blood Center, Baylor Medical School & more: http://bit.ly/3awOTbj by@steveusdin1Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
matt krebs proslijedio/la je Tweet
Disparities in FDA decisions on
$SRPT#DuchenneMuscularDystrophy therapy raise Qs about integrity of review process. CDER's Ellis Unger, who rebuffed#Vyondys, had appealed Woodcock's approval of Exondys in 2016.@BioCentury's@LaboratoryLiz reports:https://www.biocentury.com/bc-extra/company-news/2020-01-22/disparities-fda-decisions-sarepta-dmd-therapy-raise-questions- …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.